Govt lifts partial ban on Covid-19 drug, paracetamol on US request: Report

The Ministry of External Affairs and pharma industry will decide on such allocations depending on the humanitarian crisis, sources said

Hydroxychloroquine, coronavirus, covid-19, drug, drugs, pharma, pharmaceutical
The Modi government had imposed a ban on export of the drug since the coronavirus outbreak hit India.
IANS New Delhi
2 min read Last Updated : Apr 07 2020 | 10:01 AM IST
The government has decided to lift a partial ban on hydroxychloroquine after US President Donald Trump requested Prime Minister Narendra Modi to export the drug to aid America's fight against the deadly Covid-19 disease.

Official sources told IANS that the government will clear the existing orders immediately on humanitarian grounds. The Centre, sources said, will not ban but restrict the export of hydroxychloroquine and paracetamol depending on the availability of stock after meeting domestic requirements.

The Ministry of External Affairs and pharma industry will decide on such allocations depending on the humanitarian crisis, sources said.


President Trump had called Prime Minister Modi, requesting him to supply the anti-malaria drug hydroxychloroquine that is being used to treat Covid-19 patients and as prophylactic by the frontline health care workers deployed in the fight against the coronavirus pandemic. The Modi government had imposed a ban on export of the drug since the coronavirus outbreak hit India.

The US as of now has the highest number of the novel coronavirus cases in the world, with over 367,000 cases of infections and over 10,800 deaths. Relatively, India has managed to contain the pandemic with 136 deaths and over 4,700 cases of infections.
On Monday, the Donald Trump administration provided $2.9 million in aid to India to help fight against the novel coronavirus disease.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirusindian governmentparacetamolUnited StatesDonald TrumpNarendra Modi

Next Story